

Jay S Raval

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2315812/publications.pdf>

Version: 2024-02-01

100
papers

1,316
citations

331670

21
h-index

434195

31
g-index

103
all docs

103
docs citations

103
times ranked

1970
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0127771.	2.5	99
2	Pancreatic lymphoepithelial cysts express CEA and can contain mucous cells: potential pitfalls in the preoperative diagnosis. Modern Pathology, 2010, 23, 1467-1476.	5.5	64
3	Design of Asymmetric Particles Containing a Charged Interior and a Neutral Surface Charge: Comparative Study on <i>in Vivo</i> Circulation of Polyelectrolyte Microgels. Journal of the American Chemical Society, 2014, 136, 9947-9952.	13.7	46
4	Should All Massively Transfused Patients Be Treated Equally? An Analysis of Massive Transfusion Ratios in the Nontrauma Setting. Critical Care Medicine, 2017, 45, 1311-1316.	0.9	46
5	Use of a Massive Transfusion Protocol in Nontrauma Patients: Activate Away. Journal of the American College of Surgeons, 2013, 216, 1103-1109.	0.5	42
6	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019. Journal of Infectious Diseases, 2020, 222, 1620-1628.	4.0	41
7	COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion, 2021, 61, 1313-1323.	1.6	40
8	Innate Immune Activation After Transfusion of Stored Red Blood Cells. Transfusion Medicine Reviews, 2013, 27, 113-118.	2.0	39
9	Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 2014, 164, 900-902.	2.5	38
10	Intravascular Talcosis due to Intravenous Drug Use Is an Underrecognized Cause of Pulmonary Hypertension. Pulmonary Medicine, 2012, 2012, 1-6.	1.9	37
11	Basal reactive oxygen species determine the susceptibility to apoptosis in cirrhotic hepatocytes. Free Radical Biology and Medicine, 2006, 41, 1645-1654.	2.9	33
12	Simultaneous extracorporeal membrane oxygenation and therapeutic plasma exchange procedures are tolerable in both pediatric and adult patients. Transfusion, 2014, 54, 1158-1165.	1.6	33
13	Cardiac Injury Is a Common Postmortem Finding in Thrombotic Thrombocytopenic Purpura Patients: Is Empiric Cardiac Monitoring and Protection Needed?. Therapeutic Apheresis and Dialysis, 2015, 19, 87-92.	0.9	30
14	Massive Transfusion. Archives of Surgery, 2012, 147, 563-71.	2.2	29
15	ADAMTS13: origins, applications, and prospects. Transfusion, 2018, 58, 2453-2462.	1.6	29
16	Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. Journal of Clinical Apheresis, 2017, 32, 215-223.	1.3	27
17	Anesthetic Management in Upper Extremity Transplantation. Anesthesia and Analgesia, 2012, 115, 678-688.	2.2	25
18	International assessment of massive transfusion protocol contents and indications for activation. Transfusion, 2019, 59, 1637-1643.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in <scp>ADAMTS13</scp> activity. Transfusion, 2020, 60, 1308-1318.	1.6	24
20	Contemporary issues in transfusion medicine informatics. Journal of Pathology Informatics, 2011, 2, 3.	1.7	23
21	Effect of blood bank storage on the rheological properties of male and female donor red blood cells. Clinical Hemorheology and Microcirculation, 2014, 56, 337-345.	1.7	22
22	Therapeutic plasma exchange and intravenous immune globulin in the treatment of <scp>heparinâ€‘induced</scp> thrombocytopenia: A systematic review. Transfusion, 2020, 60, 2714-2736.	1.6	22
23	Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence. Frontiers in Neurology, 2021, 12, 662856.	2.4	22
24	Real-time monitoring of non-viable airborne particles correlates with airborne colonies and represents an acceptable surrogate for daily assessment of cell-processing cleanroom performance. Cytotherapy, 2012, 14, 1144-1150.	0.7	20
25	Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. American Journal of Therapeutics, 2018, 25, e270-e272.	0.9	19
26	United States Medical Licensing Examination Step 1 Two-Digit Score: A Correlation With the American Board of Pathology First-Time Test Taker Pass/Fail Rate at the University of Pittsburgh Medical Center. Archives of Pathology and Laboratory Medicine, 2011, 135, 1349-1352.	2.5	16
27	Effectiveness of an Algorithm-Based Approach to the Utilization of Plerixafor in Patients Undergoing Chemotherapy-Based Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2014, 20, 1064-1068.	2.0	16
28	Seasonal variability is not observed in the rates of high antiâ€‘A and antiâ€‘B titers in plasma, apheresis platelet, and whole blood units tested by different methods. Transfusion, 2019, 59, 762-767.	1.6	16
29	How we approach an acquired thrombotic thrombocytopenic purpura patient. Transfusion, 2014, 54, 2375-2382.	1.6	15
30	Implementation of a simple electronic transfusion alert system decreases inappropriate ordering of packed red blood cells and plasma in a multi-hospital health care system. Transfusion and Apheresis Science, 2014, 51, 53-58.	1.0	15
31	Viscoelastic testing in <scp>COVID</scp>â€‘19: a possible screening tool for severe disease?. Transfusion, 2020, 60, 1131-1132.	1.6	15
32	How do I manage longâ€‘term blood component shortages in a hospital transfusion service?. Transfusion, 2020, 60, 1897-1904.	1.6	15
33	Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise. Journal of Clinical Apheresis, 2018, 33, 291-296.	1.3	14
34	Transfusion of blood components containing ABO â€‘incompatible plasma does not lead to higher mortality in civilian trauma patients. Transfusion, 2020, 60, 2517-2528.	1.6	14
35	Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, E22.	4.1	13
36	Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee. Journal of Clinical Apheresis, 2020, 35, 25-32.	1.3	13

#	ARTICLE	IF	CITATIONS
37	How do I implement an outpatient program for the administration of convalescent plasma for <scp>COVID</scp>? Transfusion, 2022, , .	1.6	13
38	Race, rituximab, and relapse in TTP. Blood, 2022, 140, 1335-1344.	1.4	13
39	Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim. Journal of Clinical Apheresis, 2013, 28, 321-324.	1.3	11
40	Red blood cell transfusion in palliative care: what are we doing and why are we doing it?. Transfusion, 2018, 58, 3-4.	1.6	11
41	Von Willebrand factor as a thrombotic and inflammatory mediator in critical illness. Transfusion, 2020, 60, S158-S166.	1.6	11
42	Blood Product Transfusion in Adults: Indications, Adverse Reactions, and Modifications. American Family Physician, 2020, 102, 30-38.	0.1	11
43	Plasma exchange in a 13-year-old male with acute intravascular hemolysis and acute kidney injury after placement of a ventricular assist device. Journal of Clinical Apheresis, 2012, 27, 274-277.	1.3	10
44	Aged Human Stored Red Blood Cell Supernatant Inhibits Macrophage Phagocytosis in an HMGB1 Dependent Manner After Trauma in a Murine Model. Shock, 2017, 47, 217-224.	2.1	10
45	Extracorporeal photopheresis and personalized medicine in the 21st century: The future's so bright!. Journal of Clinical Apheresis, 2018, 33, 461-463.	1.3	10
46	Transfusion as a Palliative Strategy. Current Oncology Reports, 2019, 21, 92.	4.0	10
47	Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey. Journal of Clinical Apheresis, 2019, 34, 545-554.	1.3	10
48	Comparison of titer results obtained using immediate spin oneâ€dilution techniques to a reference method. Transfusion, 2019, 59, 1512-1517.	1.6	10
49	Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings. Anesthesiology, 2020, 132, 525-534.	2.5	9
50	Does Early Ambulation Increase the Risk of Pulmonary Embolism in Deep Vein Thrombosis?. Home Healthcare Nurse, 2014, 32, 336-342.	0.3	8
51	<scp>Antiâ€D</scp> alloimmunization in Rh(D) negative adults with severe traumatic injury. Transfusion, 2021, 61, S144-S149.	1.6	8
52	The impact of suctioning RBCs from a simulated operative site on mechanical fragility and hemolysis. The Korean Journal of Hematology, 2011, 46, 31.	0.7	7
53	Seasonal distribution of severe ADAMTS13 deficient idiopathic thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2014, 29, 113-119.	1.3	7
54	<scp>A</scp>pheresis education in pathology residency. Journal of Clinical Apheresis, 2017, 32, 423-428.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Biclonal IgD and IgM Plasma Cell Myeloma: A Report of Two Cases and a Literature Review. Case Reports in Hematology, 2013, 2013, 1-5.	0.4	6
56	Blood product transfusion and wastage rates in obstetric hemorrhage. Transfusion, 2018, 58, 1408-1413.	1.6	6
57	Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients. Transfusion, 2020, 60, 1676-1680.	1.6	6
58	Tolerance to incompatible ABO blood group antigens is not observed following homograft implantation. Human Immunology, 2011, 72, 835-840.	2.4	5
59	Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies. Transfusion Medicine Reviews, 2019, 33, 248-255.	2.0	5
60	Massive Transfusion Protocol Activation Does Not Result in Preferential Use of Older Red Blood Cells. Journal of Blood Transfusion, 2014, 2014, 1-5.	3.3	4
61	Factor XIII Subunit A Immunohistochemical Expression is Associated With Inferior Outcomes in Acute Promyelocytic Leukemia. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 202-205.	1.2	4
62	Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange. Therapeutic Apheresis and Dialysis, 2018, 22, 662-665.	0.9	4
63	The top 10 things to know about transfusion medicine before intern year: an evidence-based course for graduating medical students. Blood Research, 2019, 54, 125-130.	1.3	4
64	A strategy to conserve personal protective equipment while performing therapeutic plasma exchange in a patient with COVID-19. Journal of Clinical Apheresis, 2020, 35, 374-375.	1.3	4
65	Changes in mechanical fragility and free hemoglobin levels after processing salvaged cardiopulmonary bypass circuit blood with a modified ultrafiltration device. Journal of Extra-Corporeal Technology, 2012, 44, 21-5.	0.4	4
66	Pathology Consultation on Electronic Crossmatch. American Journal of Clinical Pathology, 2014, 141, 618-624.	0.7	3
67	Monitoring therapeutic apheresis utilization: Database versus registry. Journal of Clinical Apheresis, 2017, 32, 208-209.	1.3	3
68	Blood product utilization in human upper extremity transplantation: challenges, complications, considerations, and transfusion protocol conception. Transfusion, 2017, 57, 606-612.	1.6	3
69	Heparin-induced thrombocytopenia associated with collection of hematopoietic progenitor cells by apheresis. Journal of Clinical Apheresis, 2020, 35, 59-61.	1.3	3
70	The report from ASFA COVID-19 taskforce: Considerations and prioritization on apheresis procedures during the SARS-CoV-2 coronavirus disease (COVID-19) pandemic. Journal of Clinical Apheresis, 2021, 36, 878-881.	1.3	3
71	Plasma Exchange Taper for Acquired TTP Is Protective Against Recurrence at Both 30 Days and 6 Months: A Retrospective Study from 2 Academic Medical Centers. Blood, 2015, 126, 1046-1046.	1.4	3
72	Lenalidomide-associated hemolytic anemia. Leukemia and Lymphoma, 2015, 56, 2717-2719.	1.3	2

#	ARTICLE	IF	CITATIONS
73	Registry development for thrombotic microangiopathies: Biting off more than can be chewed?. Journal of Clinical Apheresis, 2017, 32, 64-65.	1.3	2
74	Reprioritising transfusion medicine education for graduating medical students. Medical Education, 2017, 51, 1163-1164.	2.1	2
75	Interval decline in hemoglobin A is associated with annual clinical event rate in sickle cell anemia patients receiving maintenance apheresis RBC exchange. Transfusion, 2019, 59, 2622-2628.	1.6	2
76	Use of therapeutic plasma exchange for pediatric neurological diseases. Journal of Clinical Apheresis, 2021, 36, 161-176.	1.3	2
77	Acute hemolytic transfusion reaction attributed to anti-At ^a . Immunohematology, 2016, 32, 140-142.	0.2	2
78	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. Blood, 2019, 134, 90-90.	1.4	2
79	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 1066-1066.	1.4	2
80	Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the <scp>AABB</scp>. Transfusion, 2022, 62, 1652-1661.	1.6	2
81	Two cases of asymptomatic massive fetomaternal hemorrhage. Transfusion and Apheresis Science, 2015, 52, 208-210.	1.0	1
82	Rainbow of hemolysis associated with acquired thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2017, 32, 274-275.	1.3	1
83	Review of whole blood use in trauma. ISBT Science Series, 2019, 14, 282-288.	1.1	1
84	Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion, 2019, 59, 2733-2748.	1.6	1
85	Total plasma volume determinations for patients with potentially challenging conditions requiring therapeutic plasma exchange: Dealer's choice. Journal of Clinical Apheresis, 2020, 35, 138-139.	1.3	1
86	Adverse event reporting for cellular therapy products: Current status and future directions. Transfusion, 2020, 60, 2815-2827.	1.6	1
87	Current advances in transfusion medicine: a 2019 review of selected topics from the AABB Clinical Transfusion Medicine Committee. Transfusion, 2020, 60, 1614-1623.	1.6	1
88	Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion, 2021, 61, 2756-2767.	1.6	1
89	Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury. Blood, 2019, 134, 444-444.	1.4	1
90	Mathematical modeling of the impact of recirculation on exchange kinetics in tandem extracorporeal membrane oxygenation and therapeutic plasma exchange. Journal of Clinical Apheresis, 2021, 36, 6-11.	1.3	1

#	ARTICLE	IF	CITATIONS
91	Complications following an unnecessary peri-operative plasma transfusion and literature review. The Korean Journal of Hematology, 2012, 47, 298.	0.7	0
92	Anesthetic Management in Upper Extremity Transplantation. Survey of Anesthesiology, 2013, 57, 207-208.	0.1	0
93	Complications following an unnecessary peri-operative plasma transfusion and literature review. Asian Journal of Transfusion Science, 2014, 8, 139.	0.3	0
94	Anesthesia and Perioperative Care in Reconstructive Transplantation. Anesthesiology Clinics, 2017, 35, 523-538.	1.4	0
95	The Impact of an Undergraduate Biology Class on Donor Recruitment at a Hospital-Based Blood Donor Center. American Journal of Clinical Pathology, 2020, 153, 368-373.	0.7	0
96	Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass?. Journal of Clinical Apheresis, 2020, 35, 236-237.	1.3	0
97	Models for plasma kinetics during simultaneous therapeutic plasma exchange and extracorporeal membrane oxygenation. Mathematical Medicine and Biology, 2021, 38, 255-271.	1.2	0
98	A little heparin goes a long way: effect of therapeutic levels of unfractionated heparin on the heparin-induced thrombocytopenia-platelet factor 4 ELISA antibody assay. Blood Coagulation and Fibrinolysis, 2021, 32, 302-303.	1.0	0
99	Editorial: Thrombotic Microangiopathies, Diagnostic and Therapeutic Advances. Frontiers in Medicine, 2021, 8, 778352.	2.6	0
100	Acute hemolytic transfusion reaction attributed to anti-Ata. Immunohematology, 2016, 32, 140-142.	0.2	0